Browse Arkansas Code titles and sections
20-15-2106. Costs — Definition.
Arkansas Code — all titles (historical 2020) · legal_authorities
20-15-2106. Costs — Definition.
(a) A manufacturer of an investigational drug, biological product, or device may:
(1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or
(2)(A) Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device.
(B) As used in this section, “costs associated with the manufacture of the investigational drug, biological product, or device” means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case.
(b) If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the manufacturer related to the investigational drug, biological product, or device.
Source: Arkansas Code — historical release 78 (November 6, 2020) · 20-15-2106
Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. A text match is a research starting point; applicability is not established.
Issuing source page ↗
Authority boundary: historical statutory source snapshot not current law.
Open the recorded source website ↗
Record provenance
Stable record: arkansas_code:legal_authorities:20-15-2106
Source file: gov.ar.code.title.20.odt
Pages: Not recorded – Not recorded
Passage SHA-256: 2c15326985d225b1585d075220586641311bdac469f3b7b64fc024521858b056
Source location: content.xml paragraph 11979
Stored source content
20-15-2106. Costs — Definition.
(a) A manufacturer of an investigational drug, biological product, or device may:
(1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or
(2)(A) Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device.
(B) As used in this section, “costs associated with the manufacture of the investigational drug, biological product, or device” means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case.
(b) If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the manufacturer related to the investigational drug, biological product, or device.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
No explicit source connection was found. This does not mean there are no relevant authorities.